^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ruserontinib (SKLB-1028)

    i
    Other names: SKLB-1028, SKLB1028, SKLB 1028
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    EGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, FLT3 inhibitor, Lyn protein-tyrosine kinase inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    ALIVE: A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated (clinicaltrials.gov)
    P3, N=315, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    cytarabine • azacitidine • fludarabine IV • Synribo (omacetaxine mepesuccinate) • aclarubicin • ruserontinib (SKLB-1028)
    almost4years
    ALIVE: A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated (clinicaltrials.gov)
    P3, N=315, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Clinical • New P3 trial
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    cytarabine • azacitidine • fludarabine IV • Synribo (omacetaxine mepesuccinate) • aclarubicin • ruserontinib (SKLB-1028)